These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 326386

  • 21. Management of breast cancer.
    Cohen IA, Keller JH, Abate MA.
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [Abstract] [Full Text] [Related]

  • 22. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.
    Manni A, Arafah B, Pearson OH.
    Cancer; 1980 Dec 15; 46(12 Suppl):2838-41. PubMed ID: 7448730
    [Abstract] [Full Text] [Related]

  • 23. Estrogen and progesterone receptor proteins in breast cancer.
    Edwards DP, Chamness GC, McGuire WL.
    Biochim Biophys Acta; 1979 Dec 19; 560(4):457-86. PubMed ID: 391286
    [Abstract] [Full Text] [Related]

  • 24. [Experimental and clinical study on endocrine therapy of breast carcinoma, with special reference to the nuclear estrogen receptor].
    Kubouchi K.
    Nihon Geka Gakkai Zasshi; 1984 Nov 19; 85(11):1405-17. PubMed ID: 6521721
    [Abstract] [Full Text] [Related]

  • 25. Hormone receptors and Japanese breast cancer.
    Matsumoto K, Kitamura Y, Sugano H.
    Acta Pathol Jpn; 1982 Nov 19; 32 Suppl 1():145-54. PubMed ID: 6764994
    [Abstract] [Full Text] [Related]

  • 26. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
    Fernandez MD, Alaghband-Zadeh J, Burn JI.
    Clin Oncol; 1983 Sep 19; 9(3):245-50. PubMed ID: 6616999
    [Abstract] [Full Text] [Related]

  • 27. Cancer of the breast. Endocrine and hormonal therapy.
    Kardinal CG, Donegan WL.
    Major Probl Clin Surg; 1979 Sep 19; 5():361-404. PubMed ID: 379452
    [Abstract] [Full Text] [Related]

  • 28. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
    Valavaara R, Tuominen J, Johansson R.
    Cancer; 1990 Dec 01; 66(11):2264-9. PubMed ID: 2147123
    [Abstract] [Full Text] [Related]

  • 29. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.
    Saez S, Martin PM, Chouvet CD.
    Cancer Res; 1978 Oct 01; 38(10):3468-73. PubMed ID: 688231
    [Abstract] [Full Text] [Related]

  • 30. Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast.
    Dao TL, Nemoto T.
    Cancer; 1980 Dec 15; 46(12 Suppl):2779-82. PubMed ID: 7448720
    [Abstract] [Full Text] [Related]

  • 31. The prediction of hormonal dependency of mammary cancer.
    Block GE, Jensen EV, Polley TZ.
    Ann Surg; 1975 Sep 15; 182(3):342-52. PubMed ID: 169754
    [Abstract] [Full Text] [Related]

  • 32. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.
    Thorpe SM.
    Acta Oncol; 1988 Sep 15; 27(1):1-19. PubMed ID: 3284552
    [Abstract] [Full Text] [Related]

  • 33. Relationship between the progesterone, androgen, and glucocorticoid receptor and response rate to endocrine therapy in metastatic breast cancer.
    Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R.
    Cancer Res; 1979 Jun 15; 39(6 Pt 1):1973-9. PubMed ID: 445396
    [Abstract] [Full Text] [Related]

  • 34. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
    Alexieva-Figusch J, Van Putten WL, Blankenstein MA, Blonk-Van Der Wijst J, Klijn JG.
    Cancer; 1988 Feb 15; 61(4):758-68. PubMed ID: 3338038
    [Abstract] [Full Text] [Related]

  • 35. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 36. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    Effi AB, Aman NA, Koui BS, Koffi KD, Traoré ZC, Kouyate M.
    BMC Cancer; 2017 Feb 07; 17(1):115. PubMed ID: 28173783
    [Abstract] [Full Text] [Related]

  • 37. Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.
    Chan SR, Fowler AM, Allen JA, Zhou D, Dence CS, Sharp TL, Fettig NM, Dehdashti F, Katzenellenbogen JA.
    Clin Cancer Res; 2015 Mar 01; 21(5):1063-70. PubMed ID: 25520392
    [Abstract] [Full Text] [Related]

  • 38. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.
    Moseley HS, Peetz ME, Keenan EJ, Awrich AE, Fletcher WS.
    Am J Surg; 1980 Jul 01; 140(1):164-72. PubMed ID: 7396080
    [Abstract] [Full Text] [Related]

  • 39. Steroid-hormone receptors in breast cancer.
    Wittliff JL.
    Cancer; 1984 Feb 01; 53(3 Suppl):630-43. PubMed ID: 6692266
    [Abstract] [Full Text] [Related]

  • 40. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O.
    Breast Cancer Res Treat; 2016 Nov 01; 160(2):313-322. PubMed ID: 27722840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.